ClinicalTrials.Veeva

Menu

Clinical Study to Evaluate Efficacy and Safety of ANT-301 in Patients With Knee Osteoarthritis in Grade III/IV by K/L

A

Anterogen

Status and phase

Active, not recruiting
Phase 1

Conditions

Osteoarthritis, Knee

Treatments

Biological: ANT-301

Study type

Interventional

Funder types

Industry

Identifiers

NCT06539429
ANT-301-102

Details and patient eligibility

About

This is a phase I open study to evaluate the efficacy and safety of ANT-301 in patients with knee osteoarthritis K&L Grade III/IV.

Full description

Study Design: open-label, single-center, dose-escalation study

Enrollment

6 estimated patients

Sex

All

Ages

19 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients who have been provided with information about the clinical trial and have provided written consent on the informed consent form
  2. Patients aged 19 to 70 years old.
  3. Patients diagnosed with K&L grade III/IV knee osteoarthritis
  4. Patients with a VAS pain score of 40mm or higher when measured on a 100-point scale

Exclusion criteria

  1. Patients with joint diseases other than osteoarthritis
  2. Patients who have undergone knee joint surgery or radiation therapy to the knee joint within 6 months prior to the screening
  3. Patients who received intra-articular injections within 6 months prior to the screening
  4. Patients who have received systemic steroid therapy within 3 months prior to the screening
  5. Patients who have received immunosuppressive agents within 3 months prior to the screening
  6. Patients who have received cell therapy or gene therapy to the target knee within 5 years prior to the screening
  7. Patients who are unwilling to use contraception during the clinical trial period

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

6 participants in 1 patient group

ANT-301
Experimental group
Description:
Vial containing allogenic adipose-derived mesenchymal stem cells and human fibrin hydrogel
Treatment:
Biological: ANT-301

Trial contacts and locations

1

Loading...

Central trial contact

Hyuksoo Han, MD. Ph D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems